MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View

Mirum Pharmaceuticals (MIRM) reported a strong Q2 2025, with a narrowed loss of $0.12 per share and revenues surging 64.1% year-over-year to $127.8 million, both exceeding analyst estimates. This outperformance was primarily driven by robust sales of its key product, Livmarli, and recently acquired bile acid products. Consequently, the company raised its full-year 2025 revenue guidance to a range of $490 million to $510 million, up from the previous $435 million to $450 million, leading to an 8.6% increase in its shares during after-hours trading.

Analysis

Mirum Pharmaceuticals (MIRM) delivered a strong second-quarter 2025 performance, significantly surpassing analyst expectations on both revenue and earnings. The company reported revenue of $127.8 million, a 64.1% year-over-year increase that beat the consensus estimate of $108 million. This top-line strength was driven by robust sales from its flagship product, Livmarli, which grew 87% to $88.2 million, and a 30% increase in sales from its recently acquired bile acid products. The company also demonstrated improved operational leverage, narrowing its net loss to $0.12 per share, which was substantially better than the estimated loss of $0.31 and the prior year's loss of $0.52. Reflecting this momentum, management raised its full-year 2025 revenue guidance to a range of $490-$510 million, a notable increase from the previous $435-$450 million projection. While operating expenses in R&D and SG&A grew by 41% and 28.7% respectively to support expansion and pipeline development, the company's cash position improved sequentially to $321.7 million, indicating a positive operational cash flow dynamic. The market reacted favorably, with the stock rising 8.6% in after-hours trading, building on a 29.1% year-to-date gain that has significantly outpaced the broader industry.

Key Decisions for Investors

• The combination of a significant revenue beat, a narrowed loss, and substantially raised full-year guidance supports a constructive thesis, and investors may view the positive market reaction as confirmation of strong operational execution.
• Monitor the sales ramp-up of Livmarli and the contribution from acquired products to ensure the company remains on track to meet or exceed its new, higher revenue guidance for 2025.
• While the current cash position appears solid, keep an eye on the growth in operating expenses relative to revenue growth to assess the company's path to sustained profitability.
• Key pipeline catalysts, particularly the top-line data from the VISTAS study for volixibat expected in the second quarter of 2026, should be tracked as potential long-term value drivers.